Literature DB >> 19716110

A positive modifier of spinal muscular atrophy in the SMN2 gene.

Thomas W Prior1, Adrian R Krainer, Yimin Hua, Kathryn J Swoboda, Pamela C Snyder, Scott J Bridgeman, Arthur H M Burghes, John T Kissel.   

Abstract

Spinal muscular atrophy (SMA) is a common autosomal-recessive motor neuron disease caused by the homozygous loss of the SMN1 gene. A nearly identical gene, SMN2, has been shown to decrease the severity of SMA in a dose-dependent manner. However SMN2 is not the sole phenotypic modifier, because there are discrepant SMA cases in which the SMN2 copy number does not explain the clinical phenotype. This report describes three unrelated SMA patients who possessed SMN2 copy numbers that did not correlate with the observed mild clinical phenotypes. A single base substitution in SMN2, c.859G>C,, was identified in exon 7 in the patients' DNA. We now show that the change creates a new exonic splicing enhancer element and increases the amount of full-length transcripts, thus resulting in the less severe phenotypes. This demonstrates that the c.859G>C substitution is a positive modifier of the SMA phenotype and that not all SMN2 genes are equivalent. We have shown not only that the SMA phenotype is modified by the number of SMN2 genes but that SMN2 sequence variations can also affect the disease severity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716110      PMCID: PMC2771537          DOI: 10.1016/j.ajhg.2009.08.002

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  29 in total

1.  An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN.

Authors:  C L Lorson; E J Androphy
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

2.  Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).

Authors:  Y Hofmann; C L Lorson; S Stamm; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

3.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

Authors:  Markus Feldkötter; Verena Schwarzer; Radu Wirth; Thomas F Wienker; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

Review 4.  Animal models of spinal muscular atrophy.

Authors:  U R Monani; D D Coovert; A H Burghes
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

5.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1.

Authors:  Luca Cartegni; Adrian R Krainer
Journal:  Nat Genet       Date:  2002-03-04       Impact factor: 38.330

6.  A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.

Authors:  Tsuyoshi Kashima; James L Manley
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

7.  Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2.

Authors:  Thomas W Prior; Kathryn J Swoboda; H Denman Scott; Ashley Q Hejmanowski
Journal:  Am J Med Genet A       Date:  2004-10-15       Impact factor: 2.802

8.  ESEfinder: A web resource to identify exonic splicing enhancers.

Authors:  Luca Cartegni; Jinhua Wang; Zhengwei Zhu; Michael Q Zhang; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

9.  Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2.

Authors:  Matthew D Mailman; John W Heinz; Audrey C Papp; Pamela J Snyder; Mary S Sedra; Brunhilde Wirth; Arthur H M Burghes; Thomas W Prior
Journal:  Genet Med       Date:  2002 Jan-Feb       Impact factor: 8.822

10.  Phase II open label study of valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Sandra P Reyna; Thomas W Prior; Bernard LaSalle; Susan L Sorenson; Janine Wood; Gyula Acsadi; Thomas O Crawford; John T Kissel; Kristin J Krosschell; Guy D'Anjou; Mark B Bromberg; Mary K Schroth; Gary M Chan; Bakri Elsheikh; Louise R Simard
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more
  111 in total

1.  Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.

Authors:  Natalia N Singh; Brian M Lee; Ravindra N Singh
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

2.  SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy.

Authors:  Chitra Iyer; Xueqian Wang; Samantha R Renusch; Sandra I Duque; Allison M Wehr; Xiaokui-Molly Mo; Vicki L McGovern; W David Arnold; Arthur H M Burghes; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2017

3.  Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy.

Authors:  Cao Yanyan; Qu Yujin; Bai Jinli; Jin Yuwei; Wang Hong; Song Fang
Journal:  J Hum Genet       Date:  2013-10-31       Impact factor: 3.172

4.  Molecular basis of purine-rich RNA recognition by the human SR-like protein Tra2-β1.

Authors:  Antoine Cléry; Sandrine Jayne; Natalya Benderska; Cyril Dominguez; Stefan Stamm; Frédéric H-T Allain
Journal:  Nat Struct Mol Biol       Date:  2011-03-13       Impact factor: 15.369

Review 5.  Disease mechanisms and therapeutic approaches in spinal muscular atrophy.

Authors:  Sarah Tisdale; Livio Pellizzoni
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

6.  Antisense oligonucleotides and spinal muscular atrophy: skipping along.

Authors:  Arthur H M Burghes; Vicki L McGovern
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

7.  The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy.

Authors:  Saif Ahmad; Yi Wang; Gouse M Shaik; Arthur H Burghes; Laxman Gangwani
Journal:  Hum Mol Genet       Date:  2012-03-14       Impact factor: 6.150

8.  Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling.

Authors:  Laura Alías; Sara Bernal; Maite Calucho; Elisabeth Martínez; Francesca March; Pia Gallano; Pablo Fuentes-Prior; Anna Abuli; Clara Serra-Juhe; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

Review 9.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

Review 10.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.